Thelansis

  Cutaneous T-cell lymphoma (CTCL), or "skin T-cell lymphomas," account for about 4 percent of all cases of NHL and primarily affect the skin, as the term indicates. In the early stages, the CTCL cells are found primarily in the skin. In patients with advanced stages of the disease, the cells may accumulate in the marrow, blood, lymph nodes, and solid organs. Mycosis fungoides (MF), which is often indolent (slow-growing) in the early stages, and a more aggressive form known as "Sézary syndrome" The two most common subtypes of CTCL are mycosis fungoides (MF), which are often indolent (slow-growing) in early stages, and a more aggressive form called "Sézary syndrome" (SS) are the two most common subtypes of CTCL. Vorinostat and romidepsin are FDA-approved for treating progressive, persistent, or recurrent cutaneous t-cell lymphoma (CTCLs). When given as single agents, these agents can induce an overall response rate of 30% to 35%. Only 2 percent to 6 perce...